Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
Launched by ZHUJIANG HOSPITAL · Apr 5, 2017
Trial Information
Current as of August 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two different surgical methods for creating a new bladder in patients with bladder cancer. The two methods being studied are the traditional ileal neobladder, which involves using a part of the intestine, and the newer detaenial sigmoid neobladder, which uses a different part of the intestine and is thought to have fewer complications. The goal of the trial is to find out which method is safer and more effective in helping patients regain urinary function after surgery.
To participate in this trial, you need to have certain types of bladder cancer and have already received some form of chemotherapy. If you are interested, you will be carefully evaluated by a urologist to make sure you're a good fit for the study. Participants can expect to receive close monitoring throughout the trial to assess their recovery and any side effects. This study is important because it aims to provide clear information on the best surgical options for patients needing a new bladder, helping to improve their quality of life after treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Bladder carcinoma in situ, include CIS and T1G3 tumor, muscle invasive bladder cancer(T2/T3N0-1M0)
- • 2. Recurrent bladder cancer
- • 3. Other conditions that have been approved by a urologist for indications for new bladder surgery
- • 4. Had been received intravesical chemotherapy, intra-arterial infusion chemotherapy or systemic chemotherapy in the past.
- • 5. Voluntarily signed the informed consent -
- Exclusion Criteria:
- • 1. Preoperative serum creatinine more than 2.26mg/dl(Or 200μmol/L)
- • 2. Cancer invaded urethral (confirmed by the pathology)
- • 3. Non - bladder cancer patients underwent neobladder
- • 4. A history of other malignant tumors within five years
- • 5. Ileum / sigmoid chronic inflammation, like ulcerative colitis or intestinal tuberculosis, and so on.
- • 6. Other conditions that have been approved by a urologist for not suitable for new bladder surgery
- • -
About Zhujiang Hospital
Zhujiang Hospital, affiliated with the Southern Medical University in Guangzhou, China, is a leading clinical research institution dedicated to advancing medical science and improving patient care through rigorous clinical trials. With a strong commitment to ethical standards and patient safety, the hospital boasts a multidisciplinary team of experienced researchers and healthcare professionals. Its state-of-the-art facilities enable the execution of innovative studies across various therapeutic areas, contributing valuable insights to the global medical community. Zhujiang Hospital aims to foster collaboration with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful development of new therapies and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Abai Xu, doctor
Principal Investigator
Zhujiang Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials